Polypid Ltd (PYPD) Stock Price, Quote & News

Company Profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in precl...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 7 4719 5700

Website: www.polypid.com

Address:

18 Hasivim Street, Petah Tikva, Israel

MarketBeat May. 13 at 6:11 PM

https://marketbeat.com/a/8652820/ $PYPD PolyPid Q1 Earnings Call Highlights

0 · Reply

Finnish_boy May. 13 at 6:08 PM

$PYPD Remember much bigger headlines from NDA submission than NDA initiation. Nice catalyst within 14 days.

0 · Reply

Finnish_boy May. 13 at 5:28 PM

$PYPD He wouldnt complain about NDA process if SP was much higher today. Bigger boys are also frusfrated😂nobody talks about this stock. Price action can be anything, flash crash to $2? I would take that

0 · Reply

Finnish_boy May. 13 at 5:25 PM

$PYPD https://sharingfromisrael.substack.com/p/an-israeli-company-built-the-treatment

0 · Reply

Finnish_boy May. 13 at 1:42 PM

$PYPD NDA submssion will wake up the markets ! Pumping start in 1-2 weeks.

1 · Reply

Finnish_boy May. 13 at 1:41 PM

$PYPD " imminently" !! Loads of attention in 1-2 weeks. SP to $5. Completion of the NDA submission to the FDA for D-PLEX₁₀₀ imminently

0 · Reply

EarningsInsider May. 13 at 1:15 PM

https://www.marketbeat.com/earnings/reports/2026-5-13-polypid-ltd-stock/ $PYPD PolyPid Earnings Transcript

0 · Reply

eureka May. 13 at 1:09 PM

$PYPD halted ??? No vol

0 · Reply

Finnish_boy May. 13 at 1:08 PM

$PYPD The thing is that they are in no hurry to sign US deal due to strong financial position. And the value goes every week up. There are multiple partners they are discussing with. So US partnership news take time. Next catalyts: NDA submssion within 2 weeks US partnership in summer NDA approval July FDA approval January

1 · Reply

StocktwitsEarnings May. 13 at 12:55 PM

$PYPD Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.35 up 50.00% YoY • PolyPid's current cash resources are expected to fund operations into the second half of 2026, supporting planned MAA submission to the EMA for D-PLEX100 in Q3 2026 and a PDUFA target action date in Q1 2027.

0 · Reply

PolyPid reports Q1 EPS (35c), consensus (43c)

May 13, 2026, 8:30 AM EDT - 6 hours ago

PolyPid Earnings Call Transcript: Q1 2026

May 13, 2026, 7:30 AM EDT - 7 hours ago

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 6, 2026, 8:00 AM EDT - 7 days ago

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

Apr 28, 2026, 8:30 AM EDT - 15 days ago

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Apr 13, 2026, 9:15 AM EDT - 4 weeks ago

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

Mar 31, 2026, 8:30 AM EDT - 6 weeks ago

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

2026-03-17T12:46:11.000Z - 2 months ago

PolyPid granted $4.3M waiver from FDA for D-Plex application

Mar 17, 2026, 8:30 AM EDT - 2 months ago

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

Mar 10, 2026, 1:40 PM EDT - 2 months ago

PolyPid Transcript: The Citizens Life Sciences Conference 2026

Feb 25, 2026, 8:35 AM EST - 2 months ago

PolyPid Announces Participation in Upcoming Investor Conferences

Feb 11, 2026, 8:30 AM EST - 3 months ago

PolyPid Earnings Call Transcript: Q4 2025

Feb 11, 2026, 7:30 AM EST - 3 months ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Jan 28, 2026, 8:00 AM EST - 3 months ago

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Jan 15, 2026, 10:30 AM EST - 4 months ago

PolyPid Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

2025-12-16T13:41:48.000Z - 5 months ago

PolyPid appoints Story as Chairman of Board of Directors

Dec 16, 2025, 8:30 AM EST - 5 months ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Dec 10, 2025, 11:30 AM EST - 5 months ago

PolyPid Transcript: KOL Event

2025-12-03T13:35:51.000Z - 5 months ago

PolyPid receives pre-NDA meeting minutes for D-Plex supporting NDA submission

Dec 3, 2025, 8:30 AM EST - 5 months ago

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

Nov 25, 2025, 8:30 AM EST - 6 months ago

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

2025-11-13T11:16:03.000Z - 6 months ago

PolyPid price target lowered to $9 from $10 at Roth Capital

Nov 12, 2025, 8:30 AM EST - 6 months ago

PolyPid Earnings Call Transcript: Q3 2025

2025-11-12T12:41:32.000Z - 6 months ago

PolyPid sees cash runway ‘well into’ 2026

2025-11-12T12:35:15.000Z - 6 months ago

PolyPid reports Q3 EPS (37c), consensus (52c)

Nov 12, 2025, 7:30 AM EST - 6 months ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 8:30 AM EST - 6 months ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Oct 29, 2025, 8:30 AM EDT - 7 months ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Sep 30, 2025, 12:30 PM EDT - 8 months ago

PolyPid Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 30, 2025, 8:45 AM EDT - 8 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 17, 2025, 8:44 AM EDT - 8 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

2025-09-16T12:45:43.000Z - 8 months ago

PolyPid completes Israeli Ministry of Health GMP inspection

Sep 16, 2025, 8:30 AM EDT - 8 months ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 3, 2025, 8:30 AM EDT - 9 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 9 months ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

2025-08-14T13:30:37.000Z - 9 months ago

PolyPid price target lowered to $13 from $15 at Craig-Hallum

2025-08-14T12:05:26.000Z - 9 months ago

PolyPid price target raised to $10 from $9 at Roth Capital

Aug 13, 2025, 8:30 AM EDT - 9 months ago

PolyPid Earnings Call Transcript: Q2 2025

2025-08-13T11:35:50.000Z - 9 months ago

PolyPid reports Q2 EPS (78c), consensus (55c)

2025-08-13T11:35:37.000Z - 9 months ago

PolyPid sees cash runway ‘well into’ 2026

Aug 13, 2025, 7:30 AM EDT - 9 months ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

2025-08-12T12:20:23.000Z - 9 months ago

PolyPid appoints Tweezer-Zaks as Chief Medical Officer

Aug 12, 2025, 8:00 AM EDT - 9 months ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Jul 30, 2025, 8:00 AM EDT - 10 months ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

2025-07-29T20:12:22.000Z - 10 months ago

PolyPid files to sell 7.63M ordinary shares for holders

Jul 15, 2025, 8:00 AM EDT - 10 months ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

2025-06-18T12:06:16.000Z - 11 months ago

PolyPid price target lowered to $9 from $12 at Roth Capital

2025-06-17T15:05:27.000Z - 11 months ago

PolyPid price target lowered to $9 from $12 at Roth Capital

2025-06-17T09:35:06.000Z - 11 months ago

PolyPid price target lowered to $14 from $16 at Citizens JMP

Jun 16, 2025, 7:20 PM EDT - 11 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 11, 2025, 9:42 AM EDT - 1 year ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 1 year ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 9, 2025, 8:54 AM EDT - 1 year ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 8:30 AM EDT - 1 year ago

PolyPid Transcript: Status Update

Jun 9, 2025, 7:30 AM EDT - 1 year ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 6, 2025, 4:05 PM EDT - 1 year ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

May 30, 2025, 10:12 AM EDT - 1 year ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 29, 2025, 10:15 AM EDT - 1 year ago

PolyPid Transcript: Lytham Partners Spring 2025 Investor Conference

May 20, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings Call Transcript: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 22, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Participate in The Citizens Life Sciences Conference

Mar 11, 2025, 7:00 AM EDT - 1 year ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 3, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the 37th Annual ROTH Conference

Feb 12, 2025, 11:20 AM EST - 1 year ago

PolyPid Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Earnings Call Transcript: Q4 2024

Feb 12, 2025, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Jan 30, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Dec 23, 2024, 7:22 PM EST - 1 year ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 11, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Nov 29, 2024, 1:05 PM EST - 1 year ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 14, 2024, 8:30 AM EST - 1 year ago

PolyPid Transcript: 2024 Sidoti Virtual Micro-Cap Conference

Nov 13, 2024, 8:30 AM EST - 1 year ago

PolyPid Earnings Call Transcript: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Oct 30, 2024, 8:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 21, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Sep 3, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Aug 14, 2024, 8:30 AM EDT - 1 year ago

PolyPid Earnings Call Transcript: Q2 2024

Aug 1, 2024, 8:31 PM EDT - 1 year ago

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

Jul 31, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

MarketBeat May. 13 at 6:11 PM

https://marketbeat.com/a/8652820/ $PYPD PolyPid Q1 Earnings Call Highlights

0 · Reply

Finnish_boy May. 13 at 6:08 PM

$PYPD Remember much bigger headlines from NDA submission than NDA initiation. Nice catalyst within 14 days.

0 · Reply

Finnish_boy May. 13 at 5:28 PM

0 · Reply

Finnish_boy May. 13 at 5:25 PM

$PYPD https://sharingfromisrael.substack.com/p/an-israeli-company-built-the-treatment

0 · Reply

Finnish_boy May. 13 at 1:42 PM

$PYPD NDA submssion will wake up the markets ! Pumping start in 1-2 weeks.

1 · Reply

Finnish_boy May. 13 at 1:41 PM

$PYPD " imminently" !! Loads of attention in 1-2 weeks. SP to $5. Completion of the NDA submission to the FDA for D-PLEX₁₀₀ imminently

0 · Reply

EarningsInsider May. 13 at 1:15 PM

https://www.marketbeat.com/earnings/reports/2026-5-13-polypid-ltd-stock/ $PYPD PolyPid Earnings Transcript

0 · Reply

eureka May. 13 at 1:09 PM

$PYPD halted ??? No vol

0 · Reply

Finnish_boy May. 13 at 1:08 PM

1 · Reply

StocktwitsEarnings May. 13 at 12:55 PM

0 · Reply

invisiblehand21 May. 13 at 12:04 PM

$PYPD nice clean earnings

0 · Reply

Finnish_boy May. 13 at 12:04 PM

$PYPD No offering until couple of major catalysts. "The Company believes its current cash resources will be sufficient to fund operations into the second half of 2026 and through several significant upcoming potential milestones." And if US deal upfront very big, then we see FDA approval before dilution.

0 · Reply

Finnish_boy May. 13 at 11:53 AM

$PYPD Today's press release in line with this (picture): they submit NDA before US partnerhip and US parnership will follow in weeks. So NDA submission about within 2 weeks, and US partnership in 3-4 weeks. Lets here the call what they comment about.

0 · Reply

Finnish_boy May. 13 at 11:47 AM

$PYPD I expect NDA submission by the end of May and US partnership news in H1 June.

0 · Reply

Finnish_boy May. 13 at 11:41 AM

$PYPD I LOVE WAITING. WAITING IS SO SO FUN. But yes, stock will double by the end of June.

0 · Reply

Finnish_boy May. 13 at 11:34 AM

$PYPD Very happy. In a couple weeks blast💥still some time to load up!!!!

0 · Reply

WallStWireAds May. 13 at 11:32 AM

$PYPD https://www.globenewswire.com/news-release/2026/05/13/3293895/0/en/PolyPid-Provides-Corporate-Update-and-Reports-First-Quarter-2026-F

0 · Reply

YoBee May. 13 at 9:56 AM

$PYPD 🤞 we get a US partner announcement today.

0 · Reply

lelXYpics May. 13 at 12:58 AM

$PYPD Rosalind's 13G https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=320037919&type=HTML&symbol=PYPD&cdn=3726053980fa1b8bff50e53bd264fe19&companyName=PolyPid+Ltd.&formType=SCHEDULE+13G%2FA&formDescription=%5BAmend%5D+Statement+of+acquisition+of+beneficial+ownership+by+individuals&dateFiled=2026-05-12

0 · Reply

newtraderlookingforhope May. 12 at 6:37 PM

$PYPD The volume here is absolutely absurd lol. Just waiting for updates, nothing more to do.

0 · Reply

Finnish_boy May. 12 at 5:29 PM

$PYPD It's about time. Lock in.

0 · Reply

Finnish_boy May. 12 at 5:19 PM

$PYPD There can be some lovely news tomorrow 7:30 AM ET. The call starts 8:30 AM.

1 · Reply

Market Cap	82.82M
Revenue (ttm)	0.00
Net Income (ttm)	-34.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.09

Volume	76,498
Avg Vol	51,680
Day's Range	N/A - N/A
Shares Out	19.08M
Stochastic %K	88%
Beta	1.41
Analysts	Strong Sell
Price Target	$12.25